๐ŸŽFREE MT2 VIAL WITH ELIGIBLE ORDERS โ€” $60 VALUE ยท LIMITED TIME
Home Products COA Library Research Insights About FAQ My Account
Products / RETATRUTIDE
99.8% PURITY THIRD-PARTY TESTED RESEARCH USE ONLY

RETATRUTIDE 10mg

$139.95 $139.95 / vial
AUSTRALIA'S TRUSTED CHOICE โœฆโœฆโœฆโœฆโœฆ
Select Strength
FREE MT2 VIAL WITH ELIGIBLE ORDERS Complimentary $60 value ยท Claim in cart ยท While stocks last ยท Research use only
Bundle quantity
View Certificate of Analysis
Same-day dispatch Orders placed before 2pm AEST on business days
Australia Post Standard 2โ€“5 business days ยท Express 1โ€“3 business days ยท Free Express shipping on orders over $100
Shipment protection included Lost or damaged in transit? We replace it, no questions asked.
Pay in 4 with afterpay Interest-free instalments over 6 weeks. Afterpay is available on our secure payment page. Select "Place Order" at checkout to view your available payment methods. Eligibility and terms apply.
ACCEPTED PAYMENT METHODS
VISA mastercard AMERICAN
EXPRESS
Overview

INDEPENDENT SAMPLE VERIFICATION

Clearly documented laboratory results.

LabDoc laboratory verification badge

LABDOC RECORD ยท LD-FSYV

Retatrutide 10mg

Independent analysis of a submitted sample

REPORT AVAILABLE

PURITY ยท HPLC
99.8%
Previously provided sample result
MEASURED CONTENT ยท HPLC
9.3 mg
Against a 10mg label claim
IDENTITY ยท LC-MS
Confirmed
Previously provided sample result
TESTING PERIOD
September 2026
Refer to the signed report for exact date

Certificate of Analysis
View the laboratory’s original report, methods and sample information.

VIEW LABDOC REPORT โ†—

Laboratory figures above are taken from Halo Bio’s previously supplied product description and must be checked against report LD-FSYV before publication. Findings apply to the submitted sample, not automatically to each stocked unit. The LabDoc badge does not imply an endorsement of Halo Bio.

HALO BIO ยท COMPOUND RESEARCH PROFILE

Retatrutide 10mg
Science, testing & documentation

Explore the molecular research behind Retatrutide (LY3437943), its distinctive three-receptor profile, published investigational studies and Halo Bio’s independent sample analysis.

Retatrutide is an investigational synthetic compound studied for simultaneous activity at the GLP-1, GIP and glucagon receptors. It is sometimes referred to as a triple-receptor agonist or โ€œTriple Gโ€. Unlike a three-compound blend, Retatrutide is one molecular entity.

Halo Bio supplies a 10mg-labelled lyophilised research material. Our published laboratory results apply to a submitted sample and can be reviewed through the linked LabDoc record below.

PRODUCT & RESEARCH SNAPSHOT

Retatrutide at a glance

Scientific name: Retatrutide ยท LY3437943
Research classification: Investigational GLP-1 / GIP / glucagon receptor agonist
Common shorthand: Reta ยท Triple G
Product presentation: 10mg-labelled lyophilised powder
Published research: Phase 2 and Phase 3 investigational studies
Laboratory record: LabDoc LD-FSYV
Fulfilment: Melbourne-held stock ยท same-day dispatch for eligible orders before 2pm

MOLECULAR RESEARCH

One compound. Three receptor pathways.

Retatrutide’s defining research characteristic is its ability to engage three signalling pathways within a single molecule. Investigators study how these receptor systems interact in metabolic regulation. The summaries below describe receptor biology, not established effects of the product supplied by Halo Bio.

GLP-1

Glucagon-like peptide-1

A receptor pathway involved in glucose-dependent insulin signalling, digestive regulation and satiety signalling.

GIP

Glucose-dependent insulinotropic polypeptide

An incretin pathway investigated for its role in insulin responses and metabolic signalling.

GLUCAGON

Glucagon receptor

A receptor associated with hepatic metabolic signalling and energy-substrate regulation.

The pharmacology of a triple-receptor agonist cannot be inferred simply by adding together the properties of three separately administered compounds.

PUBLISHED SCIENTIFIC EVIDENCE

What has been studied?

Research into Retatrutide includes laboratory pharmacology, earlier clinical development and large controlled clinical trials. These studies investigate an investigational medicinal formulation in monitored research settings; they are not tests of Halo Bio stock.

Phase 2 ยท New England Journal of Medicine (2023)

A randomised study examined Retatrutide across several investigational groups and reported changes in body weight and safety outcomes over 48 weeks. These findings supported continued investigation rather than establishing suitability for individual use.

TRIUMPH-1 ยท New England Journal of Medicine (2026)

The Phase 3 study assessed Retatrutide against placebo over 80 weeks in adults with obesity without diabetes, reporting both efficacy and adverse-event findings. Trial observations do not establish the quality, equivalence or clinical performance of independently supplied research material.

Read the Phase 2 publication โ†—

RECEPTOR PROFILE COMPARISON

Retatrutide, Tirzepatide & Semaglutide

These are distinct molecules with different receptor targets. The comparison below describes receptor activity only; it is not a ranking of safety or effectiveness.

Compound GLP-1 GIP Glucagon
Retatrutide Yes Yes Yes
Tirzepatide Yes Yes No
Semaglutide Yes No No

Comparisons between trial results require attention to different study populations, endpoints and follow-up periods. Separate studies are not direct head-to-head comparisons.

AUSTRALIAN FULFILMENT

Melbourne stock. Nationwide dispatch.

Halo Bio holds stock in Melbourne and offers same-day dispatch on eligible orders placed before 2pm on business days, following payment confirmation. Shipping estimates and tracking information are provided during fulfilment. Dispatch timing is not a guarantee of delivery time.

FREQUENTLY ASKED QUESTIONS

Retatrutide research FAQs

What is Retatrutide?

Retatrutide (LY3437943) is an investigational molecule designed to activate GLP-1, GIP and glucagon receptors.

What does โ€œTriple Gโ€ mean?

It is an informal name referring to the molecule’s three receptor targets. It does not mean the vial contains three separate compounds.

How is Retatrutide different from Tirzepatide?

Retatrutide has activity at three receptor types, while Tirzepatide targets GLP-1 and GIP. The two are distinct molecules.

What does the 10mg label mean?

It identifies the vial’s nominal labelled content. Actual measured content for a submitted sample is presented separately in the laboratory report.

What does HPLC test?

High-performance liquid chromatography can be used to assess chromatographic purity and, with an appropriate validated method, quantitative content.

What does LC-MS identity testing tell us?

Liquid chromatographyโ€“mass spectrometry provides analytical evidence relevant to identifying a compound in the submitted sample. Interpretation depends on the method and report.

Can I independently view Halo Bio’s COA?

Yes. The public LabDoc reference is LD-FSYV. Check the exact batch and test details on the official record.

Does a COA mean every vial was tested?

No. A COA ordinarily describes a particular submitted sample or batch. It does not establish that every individual vial was separately analysed.

How quickly are eligible orders dispatched?

Halo Bio offers same-day dispatch from Melbourne on eligible orders submitted before 2pm on business days, subject to stock availability and payment confirmation.

Is this research material intended for personal use?

No. Halo Bio supplies this material for laboratory research only, not human or animal consumption or clinical use.

SOURCE MATERIAL

Independent publications & documentation

  1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity โ€” Phase 2 Trial. N Engl J Med, 2023. Study โ†—
  2. Jastreboff AM et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity โ€” TRIUMPH-1. N Engl J Med, 2026. Study โ†—
  3. LabDoc independent sample record: LD-FSYV. View report โ†—

Laboratory research use only. Not intended for human or animal consumption, self-administration or clinical treatment. Published clinical research relates to controlled investigational studies, not to this independently supplied laboratory material. Confirm batch-specific results and any storage requirements using the product’s signed technical documentation.

Order total $139.95